Condition: Lung Cancer Stage III · Sponsor: University Medical Center Groningen
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for non small cell lung cancer (NSCLC), the methods used to decide who gets additional post radical (surgery or definite chemo-radiotherapy) treatment are suboptimal. Some patients get too much treatment, while others do not get enough. There is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points. The GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient. GUIDE.MRD-03-NSCLC is a part of the GUIDE.MRD project.
This description comes directly from the study's public registry record.
T.Jeroen N Hiltermann, MD, PhD · 503644936 · t.j.n.hiltermann@umcg.nl
Ed Schuuring, PhD · 503619623 · e.schuuring@umcg.nl
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Universitaire de Nice | Nice, Nice, France | Recruiting |
| Antoine Lacassagne Center | Nice, Nice, France | Not Yet Recruiting |
| Department of thoracic oncology- LungenClinic Großhansdorf | Großhansdorf, Grosshansdorf, Germany | Not Yet Recruiting |
| Isala | Zwolle, Overijssel, Netherlands | Recruiting |
| University Medical Center Groningen, Departments of Pulmonology and Pathology | Groningen, Provincie Groningen, Netherlands | Recruiting |
| Ommelander Ziekenhuis Groningen | Scheemda, Provincie Groningen, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06111807